CAI (CAI) Stock Forecast & Price Target

Caris Life Sciences is supported by strong commercial momentum, as Q2’26 revenue rose 45% Y/Y to $264M, core molecular profiling services grew 55%, and adjusted EBITDA improved to $56M with 68% gross margins. Its outlook is reinforced by rising therapy selection volumes, a successful sales force reorg, expanding territory coverage, and powerful ASP tailwinds from the $8,455 CMS reimbursement rate for MI Cancer Seek, which should drive operating leverage. The company also has a differentiated, FDA-approved multiomics platform, growing payer coverage, a promising pipeline, and a solid balance sheet with $793M of cash and positive operating cash flow, supporting profitable growth.

Caris Life Sciences is facing a negative outlook because slower-than-expected revenue contribution from the Caris Assure liquid biopsy test and weaker-than-expected Q1 volume growth of +15% Y/Y versus +21% expected suggest commercialization friction after the January sales-force realignment. Competitive pressure remains high from large, established diagnostic companies in tissue and blood testing, while litigation risk and volatility in precision oncology valuations add further downside risk. Although the company reported +85% Y/Y core revenue growth, +$33M in operating cash flow, and $826M in cash, its newer MRD and early-detection programs carry meaningful development, reimbursement, and launch risk.